Precision Biosciences has been granted a patent for engineered meganucleases targeting dystrophin genes to modify cells and treat Duchenne Muscular Dystrophy. The patent covers compositions and methods involving specific nucleic acid sequences for precise gene editing. GlobalData’s report on Precision Biosciences gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Precision Biosciences, Gene splicing using nucleases was a key innovation area identified from patents. Precision Biosciences's grant share as of May 2024 was 23%. Grant share is based on the ratio of number of grants to total number of patents.
Engineered meganucleases for modifying dystrophin gene in duchenne muscular dystrophy
A recently granted patent (Publication Number: US11993793B2) discloses a polynucleotide containing a nucleic acid sequence that encodes an engineered meganuclease capable of binding and cleaving a specific site within the dystrophin gene. This engineered meganuclease, with a defined amino acid sequence, offers potential applications in gene editing and therapeutic interventions for genetic disorders.
Furthermore, the patent also covers recombinant DNA constructs and viruses containing the polynucleotide encoding the engineered meganuclease. These constructs and viruses are designed with muscle cell-specific promoters, enhancing their targeted delivery and potential efficacy in treating genetic conditions related to the dystrophin gene. The inclusion of specific capsid proteins in the recombinant AAV virus further highlights the precision and customization possible with this technology, offering a promising avenue for future gene therapy developments in the field of genetic medicine.
To know more about GlobalData’s detailed insights on Precision Biosciences, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
